Monday 13 August 2018

Reuters Health Report: Australia's Nufarm shares plunge 17 percent after Monsanto weedkiller cancer finding

Reuters.com Newsletter

Australia's Nufarm shares plunge 17 percent after Monsanto weedkiller cancer finding

A Californian court finding that a Monsanto weedkiller caused cancer in a school groundskeeper sent shares in an Australian maker of a similar product, Nufarm Ltd, tumbling almost 17 percent to a more than two-year low on Monday.

Monsanto ordered to pay $289 million in world's first Roundup cancer trial

A California jury on Friday found Monsanto liable in a lawsuit filed by a man who alleged the company's glyphosate-based weed-killers, including Roundup, caused his cancer and ordered the company to pay $289 million in damages.

Four new Congo Ebola cases as medics prepare experimental treatment

Four new cases of Ebola virus have been confirmed in eastern Democratic Republic of Congo, the health ministry said, as authorities prepare to deploy an experimental treatment.

India's Hetero pulls heart drug from U.S. amid cancer risk probes

A unit of India's Hetero Drugs is recalling some batches of the blood pressure and heart medicine valsartan in the United States, a notice on the U.S. regulator's website said, amid a wider probe into cancer risks associated with the drug.

Amicus Therapeutics receives U.S. approval for Fabry disease drug

U.S. health regulators on Friday approved Amicus Therapeutics' Galafold, the first oral therapy to treat Fabry disease, a rare, sometimes fatal condition in which accumulation of fat damages several organs.

Girls with obesity have increased risk of depression

(Reuters Health) - Obese girls are more likely to develop depression during childhood and adolescence than their peers who weigh less, a research review suggests.

Osteoporosis drugs tied to lower fracture risk and health costs

(Reuters Health) - Older women with osteoporosis who consistently take medications for the condition may have a lower risk of fractures and lower total health costs than their counterparts who stop taking these drugs, a U.S. study suggests.

Alnylam's gene silencing drug wins FDA approval

Alnylam Pharmaceuticals Inc's drug for a rare hereditary disease won U.S. regulatory approval on Friday, becoming the first approved treatment from a new class of medicines that use gene silencing technology.

Manager support of employees with depression may reduce absenteeism

(Reuters Health) - In a working environment where managers feel comfortable offering help and support rather than avoiding employees with depression, absenteeism is lower and presenteeism is higher, according to a study covering 15 countries.

EU says second China company made tainted heart drug

The European Medicines Agency (EMA) said on Friday that a second Chinese contract manufacturer, Zhejiang Tianyu, had produced a common blood pressure and heart drug with an impurity that could cause cancer.

College-age students unsure when fertility declines

(Reuters Health) - Most university students may plan to have children in the future, but they also probably overestimate how much time they have before their fertility starts to wane, an Australian study suggests.

Related Videos

Vatican now opposes death penalty in all cases

'Guardians' stars out to save their fired director

Introducing the all-new
Reuters News app

The new Reuters News app is here, redesigned from the ground up to fit your busy life.

Get it now on iOS